Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1678407 | 0.90 | RXRA (0.46) | KDM4ENPSR1MAPTRXRARXRB | |
| SCHEMBL3827737 | 0.87 | TBXAS1 (0.43) | KDM4EPTGDR2RXRARXRBNR4A2 | |
| SCHEMBL3821918 | 0.86 | MAPT (0.39) | KDM4ENPSR1MAPTGAATDP1 | |
| SCHEMBL3826332 | 0.83 | DHFR (0.42) | KDM4ENPSR1MAPTGAA | |
| SCHEMBL5094734 | 0.82 | ADORA1 (0.39) | KDM4EPTGDR2NPSR1MAPTGAA | |
| SCHEMBL3820863 | 0.82 | DHFR (0.43) | KDM4ENPSR1MAPTGAA | |
| SCHEMBL5089708 | 0.82 | FAAH (0.40) | KDM4EPTGDR2MAPTRXRARXRB | |
| SCHEMBL6112415 | 0.81 | GABRA2 (0.48) | KDM4EGAAPTGESALOX5 | |
| SCHEMBL5095459 | 0.81 | KDM4E (0.47) | KDM4ENPSR1MAPTRXRARXRB | |
| SCHEMBL5094874 | 0.79 | NR4A2 (0.38) | KDM4EPTGDR2NPSR1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581535-B3 | PYRROLOPYRIDAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2009-09-02 | — | — | EP | disclosed |
| EP-1581535-B9 | PYRROLOPYRIDAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-03-19 | — | — | EP | disclosed |
| US-7317009-B2 | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC. (JP) | 2008-01-08 | — | — | US | disclosed |
| EP-1581535-B1 | PYRROLOPYRIDAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20060270678-A1 | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1581535-A1 | PYRROLOPYRIDAZINE DERIVATIVES | Astellas Pharma Inc. (JP) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004063197-A1 | PYRROLOPYRIDAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270678-A1 | Pyrrolopyridazine derivatives | PDE4A, PDE5A, PDE12 | KDM4E 1703/4885PTGDR2 142/4885NPSR1 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.